RT Journal Article
T1 Cost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population
A1 Oyagüez, Itziar
A1 Gómez-Peralta, Fernando
A1 Artola, Sara
A1 Carrasco, Francisco J.
A1 Carretero-Gómez, Juana
A1 García-Soidan, Javier
A1 Gómez-Huelgas, Ricardo
A1 Merino-Torres, Juan F.
A1 Pérez, Antonio
K1 Cost
K1 Diabetes
K1 Flash
K1 FreeStyle libre
K1 Glucose monitoring
K1 Costes y análisis de costes
K1 Automonitorización de la glucemia
K1 Diabetes mellitus tipo 2
K1 Población
K1 Insulina
AB Introduction: FreeStyle Libre 2 system is a sensor-based flash-monitoring system that measures interstitial fluid glucose. The study aimed to compare cost of FreeStyle Libre 2 system and self monitoring of blood glucose (SMBG) in the type 2 diabetes mellitus (T2DM) population from the Spanish Health System perspective. Methods: On the basis of data collected from a literature review, the cost of glucose monitoring was modelled for patients with T2DM on a basal-bolus insulin regimen. The cost estimate included annual consumption for glucose monitoring (strips, lancets and sensors) and severe hypoglycaemic events (SHE) manage ment. A published rate of SHE (2.5 episodes/patient-year) was considered. A reduction of SHE (- 48.8%) associated with FreeStyle Libre 2 system, derived from the REPLACE trial, was applied. Hospital attendance for 20.5% of SHEs (with subsequent hospital ization in 16.0%) was applied. Consumption of strips and lancets was set at 6/day for SMBG (derived from national monitoring recommendations), and 0.2/day for FreeStyle Libre 2 sys tem users, with 26 FreeStyle Libre 2 sensors/ year. Unitary costs (€, year 2020 excluding VAT) were derived from literature (€0.28/strip; €0.09/ lancet; €3.09/daily FM sensor; €3804/hospital ized SHE; €1794/hospital-attended non-admit ted SHE; €389/community-attended SHE). Results: Costs were €2700 and €2120/year/pa tient using SMBG or FreeStyle Libre 2 system, respectively. For 1000 patients with T2DM using basal-bolus insulin, 1220 SHEs/year (with 48 hospitalizations) could be prevented and FreeSytle Libre 2 system could generate cost savings of up to €580,953/year versus SMBG (- 21.5%) Conclusion: FreeStyle Libre 2 system is a potential cost-saving strategy in patients with T2DM in Spain on a basal-bolus insulin regimen.
SN 1869-6953
YR 2021
FD 2021-05-04
LK http://hdl.handle.net/10668/3985
UL http://hdl.handle.net/10668/3985
LA en
NO Oyagüez I, Gómez-Peralta F, Artola S, Carrasco FJ, Carretero-Gómez J, García-Soidan J, et al.  Cost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population. Diabetes Ther. 2021 Sep;12(9):2329-2342
DS RISalud
RD Apr 7, 2025